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Background: Studies of the difference between menstrually associated and non-menstrually associated migraine
are somewhat controversial. The majority of studies have focused on comparing menstrual to non-menstrual attacks
rather than comparing study groups with different migraine diagnoses with respect to menstruation. As there is
limited knowledge available on the overall impact and burden of migraine among groups of women with and
without menstrually associated migraine our goal was to examine differences between these groups. We hypothesized
that there would be greater burden of migraine related to menstruation and headache frequency in a population study
across groups of women.
Methods: We analyzed data from the American Migraine Prevalence and Prevention (AMPP) Study, a longitudinal,
US, population-based study. We included female respondents to the 2009 survey, aged 18 to 60, who met modified
ICHD-2 criteria for migraine, were actively menstruating and fit one of three definitions based on the self-reported
association of menses and migraine attacks: self-reported predominantly menstrual migraine (MM, attacks that only or
predominantly occur at the time of menses), self-reported menstrually-associated migraine (MAM, attacks commonly
associated with menses, but that also occur at other times of the month), and self-reported menstrually-unrelated
migraine (MUM). These three groups were compared on characteristics and measures of headache impact and burden
(Headache Impact Test– 6 item (HIT-6) and Migraine Disability Assessment Scale (MIDAS).
Results: There were 1,697 eligible subjects for this study in the following categories: MM (5.5%), MAM (53.8%), or
MUM (40.7%). Women with MM had an older age of migraine onset. Those with predominantly menstrually-related
attacks (MM) had fewer headache-days but appeared to be more impaired by attacks. HIT-6 and MIDAS scores were
significantly higher for both the MM and MAM groups compared with the MUM groups; however, effects were more
robust for MM than MAM.
Conclusions: Nearly 60% of women with migraine reported an association between migraine and menses. These
women reported greater headache impact and migraine-related burden on functioning than those in whom migraines
were not related to menstruation. Women with MM were more impaired by attacks while women with MAM had
overall highest burden, likely due to experiencing migraines on additional days.
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Table 1 Headache and menstrual cycle definitions
American Migraine Prevalence and Prevention Study, 2009
Self-reported definitions used in this paper
Self-reported predominantly
Menstrual migraine (MM)
Headaches in relation to your period:
“all of my headaches are related to my
menstrual cycle”(my headaches ONLY
happen around the time of my period
(from two days before to three days
after the start of menstruation)
Self-reported Menstrually-
associated migraine (MAM)
Headaches in relation to your period:
“I am more likely to get headaches with
my period but they also occur at other
times of the month”
Self-reported Menstrually-
unrelated migraine (MUM)
Headaches in relation to your period:
“my headaches are not related to my
menstrual cycle”
International Headache Society (ICHD-3beta) [2]
Diagnostic Criteria
Pure menstrual migraine Documented and prospectively
collected evidence that attacks occur
exclusively on day 1 ± 2 (i.e., days -2
to +3)1 of menstruation in at least
two out of three menstrual cycles
and at no other times of the cycle
Menstrually-related migraine Documented and prospectively
collected evidence that attacks occur
on day 1 ± 2 (i.e., days -2 to +3)1 of
menstruation in at least two out of
three menstrual cycles and additionally
at other times of the cycle
Non-menstrual migraine Attacks have no menstrual relationship
1- The first day of menstruation is day 1 and the preceding day is day -1; there
is no day 0.
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Many women with migraine report an association be-
tween migraine attacks and menses. These attacks have
been referred to as “menstrual” migraine by both pa-
tients and clinicians and have been the focus of an
evolving definition of Menstrual Migraine by the Inter-
national Classification of Headache Disorders (ICHD-2)
[1,2]. The proportion of women with menstrually-related
migraine varies among studies from 3% [3] to 76% [4],
depending upon study populations and diagnostic cri-
teria used. The use of broad encompassing case criteria
may mask a severity effect, especially if the effect is con-
fined to a more narrowly defined menstrual migraine
subgroup. Clinical experience and results from clinic
based studies support that peri-menstrual migraine at-
tacks are more severe [3,5-7], longer in duration [3,8-10],
have greater associated impairment [9,10] and are more
difficult to treat [3,8,10] than migraine attacks at other
times of the month.
There has been a long-standing preconception that
this severity of menstrually associated migraines shown
in clinical studies has not been seen in population-based
studies [11-13]. The common explanations for this have
been the selection bias in specialty clinics and the out-
comes that were measured to represent dimensions of
severity (e.g., pain intensity, pain duration, symptoms,
disability, etc). Lack of precise menstrual migraine diag-
noses and frequent variability in interpretation of the
diagnoses among researchers has added to the confu-
sion. Furthermore, the majority of prior population and
clinic-based studies comparing menstrual to non-
menstrual migraine have been based on prospective diar-
ies and have focused on comparing menstrual attacks to
non-menstrual attacks [6,10,11,14,15], rather than com-
paring different groups of migraineurs [3]. Therefore, it
was the goal of this study to examine the severity and
associated burden/impact of migraine across groups that
are variously affected by menstruation, rather than only
across attacks. The diagnostic criteria for menstrual mi-
graine are still evolving and remain in the appendix of
the ICHD-3beta [2] with the requirement for prospective
documentation of the association of migraine attack and
menses with three months of diary data. Since no popu-
lation study has obtained three month menstruation re-
lated diary data on more than a hundred women, there
is value in examining subgroups of women based on
their self-reported relationship of migraine to menstru-
ation as commonly occurs in clinical settings.
In the present study, we used self-reported data from
the 2009 American Migraine Prevalence and Prevention
(AMPP) Study [16] to define three groups of women
with migraine using criteria and definitions that are
different, but in spirit consistent with the ICHD criteria
[2] (Table 1): self-reported predominantly menstrualmigraine (MM) for headaches that occur with menses
(two days before to three days after the start of menstru-
ation), self-reported menstrually-associated migraine
(MAM) for headaches associated with menses, but that
also occur at other times of the month, and self-reported
menstrually-unrelated migraine (MUM). We then com-
pared these three groups to determine if there was vari-
ation in the impact (Headache Impact Test– 6 item
[HIT-6]) and migraine-related disability (Migraine Dis-
ability Assessment Scale [MIDAS]). We hypothesized
that the association with menses will contribute to sig-
nificant burden of migraine and that women with MAM
will experience the most significant burden because they
have menstrually-related attacks as well as attacks out-
side of the menstrual window.
Methods
The AMPP Study was approved by the Albert Einstein
College of Medicine Institutional Review Board. The
AMPP Study was modeled on the methods of the
American Migraine Studies I [17] and II [18], described
in detail elsewhere [16] and briefly summarized herein.
In 2004, a screening survey was mailed to a stratified
random sample of 120,000 U.S. households encompassing
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completed by the head of the household, who reported
the total number of household members and the number
of household members experiencing at least occasional
self-defined “severe headache”. Each household member
with severe headaches was asked to complete a question-
naire that included questions the AMS/AMPP diagnostic
module which allows for assignment of migraine based
upon on modified ICHD-2 criteria. This module has been
demonstrated to have a sensitivity of 100% and specificity
of 82% for the diagnosis of migraine [19]. No significant
changes occurred between ICHD-2 and ICHD-3beta that
are related to the criteria used in this study.
A random sample of 24,000 of the adult (i.e., ≥18 years
of age) respondents to the 2004 survey who self-reported
active (i.e., past 12 months) “severe headache” were asked
to participate in an annual longitudinal follow up study.
They completed questionnaires annually from 2005-2009.
We used the 2009 AMPP Study survey because complete
data were available to describe subtypes of menstrual mi-
graine and it included the HIT-6 (with paid permission for
use) as well as the MIDAS.
In the 2009 survey, respondents answered questions
about headache symptoms, frequency, severity, men-
strual status and whether they had headache/migraine
associated with menstruation, employment status (i.e.,
working for pay full- or part-time, unemployed, retired,
a student, a homemaker, disabled, a volunteer, on med-
ical or maternity leave, or “other”) and completed the
MIDAS [20] and HIT-6 questionnaire [21]. 17,052 fe-
males were mailed the 2009 AMPP Study questionnaire
and 71.4% (n = 12,180) were completed and returned
(Figure 1).
Respondents were asked to indicate the number of
days they had headache in the preceding three months
and the number of days with their “most severe type of
headache” over the preceding year. A total of 5,134 fe-
male respondents of the 2009 AMPP Study survey met
criteria for episodic migraine and were considered active
cases (i.e., defined as having at least one migraine in the
previous 12 months and an average of <15 headache
days per month over the preceding 3 months). Of these,
1,697 were eligible for this analysis which included
the following: aged 18 to 60 years, had at least one
menstrual cycle in the preceding two months, and
responded to the questions used to determine menstrual
migraine status.
Menstrual migraine subgroups
The diagnostic criteria for migraine in association with
menses have not been firmly established; as a conse-
quence in ICHD-3beta [2] (Table 1) the criteria remain
in the Appendix, indicating that they are not yet fully ac-
cepted, but intended for further study. We could notapply ICHD-3beta criteria as written because we relied
on self-reported recall of headaches associated with
menses, a common approach both in large scale epi-
demiological studies and in clinical care. Our large scale
study does not include daily diaries as recommended by
ICHD-3beta criteria in order to establish a diagnosis.
The AMPP Study questionnaire asked, “Which state-
ments best describe your headaches in relation to your
period?” Respondents were classified into three mutually
exclusive groups based on their responses. Women who
selected “all of my headaches are related to my men-
strual cycle (my headaches ONLY happen around the
time of my period from two days before to three days
after the start of menstruation)” were assigned to the
self-reported predominantly menstrual migraine (MM)
group. Women who selected “I am MORE LIKELY to get
headaches with my period but they also occur at other
times of the month” were assigned to the self-reported
menstrually-associated migraine (MAM) group unless
they also endorsed the MM statement. Finally, women
who selected “my headaches are NOT related to my
menstrual cycle” were assigned to the self-reported
menstrually-unrelated migraine (MUM) group if they
did not also endorse the MM or MAM statement. An-
other difference between how we defined our subgroups
and ICHD-3beta criteria is that we did not require
women to endorse “I get headaches with at least two of
every three periods” as these data were not collected.
We did not exclude women who endorsed more than
one response option. Of respondents who endorsed the
response “My headaches ONLY happen around the time
of my period [from two days before to three days after the
start of menstruation]” about one third also endorsed “I
am MORE LIKELY to get headaches with my period but
they also occur at other times of the month”. Simultan-
eous endorsement of both statements most likely occurs
in women who have predominantly MM with occasional
migraine and/or headaches at other times. Accordingly,
we assigned these women to the self-reported predomin-
antly MM group (MM). This decision and its potential
consequences are considered in the discussion. “I am
MORE LIKELY to get headaches with my period but they
also occur at other times of the month” and “my head-
aches are NOT related to my menstrual cycle” were both
endorsed by 4.1% of the cases and these women were
assigned into the MAM group. This is likely conserva-
tive since these cases likely decreased the strength of
observed associations.
Number of migraine attacks and days with migraine/
headache
Headache attack frequency was based on a response to a
question about the number of days with headache (for
most severe type of headache) in the past month, three
Figure 1 2009 AMPP female respondents and group assignment.
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headaches per month. Headache-days in the past three
months was taken from the response to a MIDAS ques-
tion on the number of days with headache in the past
three months (one migraine attack could last for mul-
tiple days).
Headache impact on functioning
We used the following migraine/headache impact mea-
sures: MIDAS (scored by grade), a MIDAS measure of
lost productive time (LPT) [22,23] and the HIT-6 [21].
Migraine-related disability
The MIDAS is comprised of five questions related to im-
pact of migraine/headache on functioning in defined
roles (i.e., housework, work for pay, leisure time) [20]
that are used to categorize severity into four grades
based on total days of impaired functioning (i.e., Grade I
or little or no disability, 0 to 5; Grade II or mild disabil-
ity, 6 to 10; Grade III or moderate disability, 11 to 20;Grade IV or severe disability, ≥21, with an option of div-
iding Grade IV into IVA and IVB). The recall period for
the MIDAS is three months, effectively covering three
menstrual cycles.
Lost productive time
We used the two MIDAS work-for-pay questions to esti-
mate lost productive time (LPT). These two questions
ask about number of days of missed work in the past
three months due to headache (absenteeism) and num-
ber of days while at work where productivity was re-
duced by half (presentism denoted as Half Days) or
more because of headache.
Employment
Employment status was documented [22] for each re-
spondent and defined as actively employed for pay (i.e.,
excludes those on short- or long-term medical leave) if
they reported actively working enough hours to qualify
for full- (≥35 hours) or part-time (20 to 34 hours) status
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eligible for employment but “unemployed” if they re-
ported they were either unemployed or on medical dis-
ability. For analysis, employment was defined as a binary
variable (i.e., employed versus unemployed).
We also used the HIT-6, (with a licensing fee) which is
comprised of six questions, to assess the impact of the
most severe headache type on ability to function. Three
questions are independent of headache frequency and
three questions are related to frequency of headache at-
tacks. It has a recall period of four weeks [21]. It should
be noted that both MIDAS and HIT-6 impact measures
do not specifically assess headache or migraine days re-
lated to menstruation, but all headache-days over an
interval of 3 months and 1 month, respectively.
Analyses
The analysis was confined to women who both met cri-
teria for migraine and had menstrual cycles in the two-
month period before completing the 2009 AMPP Study
survey. We compared the three subgroups defined by
self-reported menstrual headache status (i.e., MM,
MAM, MUM) on characteristics and measures of head-
ache impact.
LPT was defined as: Missed Work Days + 0.5*(Work-
days Where Productivity was Reduced by Half )
The LPT formula is for the number of missed workday
equivalents in the three months before the survey. We
assumed that a workday reduced by half or more is
equivalent to working for half of a usual workday, an es-
timate that was validated in a previous diary study [20].
Based on previous experience [22,23] and given the non-
normal distribution properties of work loss (i.e., a sub-
stantial proportion with no work loss), LPT was defined
as two binary variables (i.e., < 0.5 LPT Days versus 0.5+
LPT days and < 2 LPT Days versus 2+ LPT days). For
analysis, employment was defined as a binary variable
(i.e., employed versus unemployed). We applied the stand-
ard scoring algorithm for HIT-6 items where responses
are assigned values (i.e., Never = 6, Rarely = 8, Some-
times = 10, Very Often = 11, Always = 13) and summed
for a total score. We stratified respondents using the
standard cut-points. (i.e., <50 = little or no impact, and 50
to 55 for some impact, 56 to 59 for substantial impact, ≥60
for very severe impact). We completed regression analysis
using cut-points above and below 56 (i.e., <56, ≥56) and 60
(i.e., <60, ≥60).
We used chi-square to compare the sociodemographic
and headache characteristics of the three subgroups, and
we used logistic regression (i.e., LPT, HIT-6 item vari-
ables) to analyze the relationship between menstrual mi-
graine status and measures of headache impact, as
previously defined. We completed separate logistic re-
gression models for women who reported six or fewerheadache-days in the past three months (i.e., an average
of two headache-days per month) and for all women
with EM (i.e., ≤45 headache-days in three months). Co-
variates were added in two sequential models that in-
cluded: 1) age (18 to 29, 30 to 39, 40 to 49, 50 to 60);
race (White, Black, Other); education (no high school
diploma, high school diploma, some college or associates
degree, bachelors degree, graduate degree); annual house-
hold income (< $22,500, $22,500to $39,999, $40,000 to
$59,999, $60,000 to $89,999, ≥ $90,000), and age at mi-
graine onset; and 2) number of attacks of the most severe
type of headache in the past month. SAS version 9.2 was
used for all analyses (SAS Institute Inc., Cary, NC).
Results
Among the 1,697 respondents who met inclusion criteria
(Table 2), 5.5% (n = 93) were categorized as MM, 53.8%
(n = 913) as MAM, and 40.7% (n = 691) as MUM using
the criteria presented in Table 1. Overall, the three
groups significantly differed by education, annual house-
hold income, number of headache types, and age of on-
set of migraine. Those in the MAM group tended to
have a higher education level, whereas those in the MM
group tended to have a higher income. Women with
MM had fewer headache types and a later age of mi-
graine onset (i.e., 34.4% on or after age 30 versus <24.0%
for the other two groups). Menstrual migraine association
status was not associated with other covariates. The num-
ber of headache-days in the past three months differed
significantly among the three groups (Table 3). In the MM
group, 68.8% of cases had six or fewer headache-days in
the past three months compared to 53.3% for MAM cases
and 61.7% for MUM cases (p < 0.001). In the MAM group,
persons with ≥15 headache-days in the past three months
were more common (p < 0.001). The distribution by num-
ber of headache attacks is difficult to compare by group
because of the variation in percent with unknown values.
In particular, 17.2% of MM cases had an unknown value.
Furthermore, the difference in distribution by number of
headache-days is an artifact, in part, of the case definition
for MM (i.e., “my headaches ONLY happen around the
time of my period [from two days before to three days after
the start of menstruation]”).
Headache impact
Impact measures, which were dependent on headache-
days, also differed by menstrual migraine status. Specific-
ally, the distribution by the four MIDAS Grades varied
significantly by menstrual migraine status (chi-square
p < 0.001). Proportionately more MAM (23.8%) and MM
(16.1%) cases had MIDAS scores which classified them as
Grade III or IV (moderate or severe) compared to MUM
(15.4) cases. The unemployment rate (i.e., looking for
work but not employed/[looking for work + employed])
Table 2 Sociodemographic and headache characteristics by menstrual group in women with episodic migraine who are
actively menstruating: results from the AMPP 2009 Survey












(MUM) (N = 691)
Age, years
<30 196 11.6% 10 10.7% 103 11.3% 83 12.0%
30-39 554 32.6% 22 23.7% 289 31.6% 243 35.2%
40-49 748 44.1% 44 47.3% 410 44.9% 294 42.6%
50-60 199 11.7% 17 18.3% 111 12.2% 71 10.3%
Race
White 1495 88.1% 77 82.8% 811 88.8% 607 87.8%
Black 118 7.0% 11 11.8% 59 6.5% 48 6.9%
Asian, Pacific Islander 28 1.6% 2 2.2% 13 1.4% 13 1.9%
Other 27 1.6% 1 1.1% 17 1.9% 9 1.3%
Unknown 29 1.7% 2 2.2% 13 1.4% 14 2.0%
Education1
High school grad or less 375 22.1% 25 26.9% 176 19.3% 174 25.2%
Some college 412 24.3% 22 23.7% 216 23.7% 174 25.2%
Bachelor degree 639 37.6% 29 31.2% 373 40.8% 237 34.3%
Graduate degree 240 14.1% 14 15.1% 133 14.6% 93 13.5%
Unknown 31 1.8% 3 3.2% 15 1.6% 13 1.9%
Current Employment Status2
Full-time 958 56.2% 47 50.5% 520 57.2% 391 56.6%
Part-time 269 16.1% 22 23.7% 154 16.9% 93 13.5%
Unemployed 248 14.3% 13 14.0% 113 12.4% 122 17.7%
Other 218 13.2% 11 11.8% 122 13.4% 85 12.3%
Annual Household Income3
<$22,500 248 14.6% 16 17.2% 108 11.8% 124 17.9%
$22,500-$39,999 321 18.9% 16 17.2% 176 19.3% 129 18.7%
$40,000-$59,999 403 23.7% 18 19.4% 225 24.6% 160 23.2%
$60,000-$89,999 331 19.5% 16 17.2% 196 21.5% 119 17.2%
≥$90,000 394 23.2% 27 29.0% 208 22.8% 159 23.0%
Body Mass Index
Underweight 81 4.8% 1 1.1% 45 4.9% 35 5.1%
Normal 571 33.6% 27 29.0% 328 35.9% 216 31.3%
Overweight 431 25.4% 28 30.1% 233 25.5% 170 24.6%
Obese 614 36.2% 37 39.8% 307 33.6% 270 39.1%
Headache Types4
1 455 26.8% 42 45.2% 225 24.6% 188 27.2%
2 772 45.5% 32 34.4% 432 47.3% 308 44.6%
≥3 413 24.3% 12 12.9% 232 25.4% 169 24.5%
Unknown 57 3.4% 7 7.5% 24 2.6% 26 3.8%
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Table 2 Sociodemographic and headache characteristics by menstrual group in women with episodic migraine who are
actively menstruating: results from the AMPP 2009 Survey (Continued)
Age of Onset – most severe headache5
<15 351 20.7% 13 14.0% 218 23.9% 120 17.4%
15-19 316 18.6% 15 16.1% 182 19.9% 119 17.2%
20-24 272 16.0% 5 5.4% 143 15.7% 124 17.9%
25-29 190 11.2% 11 11.8% 97 10.6% 82 11.9%
≥30 384 22.6% 32 34.4% 192 21.0% 160 23.2%
Unknown 184 10.8% 17 18.3% 81 8.9% 86 12.5%
1 – Chi -square p = 0.035 for education level, when include unknowns p = 0.064.
2 – Chi-square p = 0.019 for employment status; “Unemployed” encompasses reported unemployed and those on medical leave. “Other” includes homemaker,
retired, student, volunteer and other. Self-employed was included in the full time employed group.
3 – Chi-square p = 0.028 for household income.
4 – Chi-square p < 0.001 for headache type (including/excluding unknowns).
5 – Chi-square p = 0.001 for age of onset of most severe headache type (including/excluding unknowns).
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MM cases (17.7%) compared to the other two groups
(12.4% to 14.0%). In univariate analysis, only distribution
by the MIDAS LPT measure differed among the three mi-
graine groups (p < 0.001) (Table 3).
The three migraine subgroups differed by age,
headache-days, and other factors that could confound
the comparison on measure of functional impact. We
completed logistic regression models (i.e., comparing
MM and MAM cases to MUM cases) using measures of
headache impact as the outcome for respondents with
six or fewer headache-days in the past three months
(58.5% of all cases and 68.8% of MM cases) and then
for all EM cases (headache-days frequency per three
months <45) (Table 4). The odds ratios did not differ for
those with six or fewer headache-days/three months
compared to all EM cases. We also adjusted for all co-
variates except for headache attack frequency (Model I)
and then again by including headache attack frequency
(Model II). The odds ratios were similar for models
without (Model I) and with (Model II) adjustment for
headache attacks in the previous month. Among those
with six or fewer headache-days/three months (model
1), statistically significant elevated odds ratios were ob-
served for MIDAS LPT (OR = 2.4, 95% CI: 1.1-5.1) and
for a HIT-6 score of 56+ (OR = 2.5; 95% CI: 1.3-4.7)
among MM cases (p < 0.01). Odds ratios for MAM cases
were consistently lower than that of MM cases and were
less often statistically significant.
Discussion
To assess burden of migraine in the population, we
compared three groups of women with migraine based
on the self-reported association of their migraine attacks
with menses using data from the AMPP Study. The
majority of women reported some association of mi-
graine with menses, though in most, migraine also
occurred at other times of the month. Those withpredominantly menstrually-related attacks (MM) had
fewer headache-days but appeared to be more impaired
by attacks as measured by impairment in ability to work
and elevated HIT-6 scores. Women with MAM had
overall highest burden, due to experiencing not only
peri-menstrual migraines but additional migraines out-
side of the peri-menstrual window.
Women with MM had fewer headache-days per three
months, as was expected given the case definition for
MM. In contrast, the MAM group had the highest num-
ber of headache-days per three months. This pattern
may be important when interpreting findings for the
MIDAS LPT headache-days adjusted measure and the
HIT-6 measure (Table 4). These measures reflect, in
part, the frequency of headaches, as well as, the impact
that headaches have on functioning. The adjusted odds
ratios for MIDAS LPT were statistically significant and
indicate that women with MM experience headaches
that have a substantial impact on the work role that is
more disabling than that of the other two subgroups.
Moreover, as the threshold for work impact was in-
creased (i.e., missed days of work or absenteeism), the
difference between MM cases and other cases increased,
a finding that is consistent with specialty clinic [9,10]
and population studies [3,24]. The HIT-6 measures the
global impact of headaches on the social role and other
domains of functioning and includes a measure of pain.
The elevated odds ratios for a “severe impact” HIT-6
score (≥56) is consistent with the above findings for
MIDAS and suggests a more general impact on func-
tioning from MM than the work role.
Previous diary studies compared all peri-menstrual
headaches to headaches at other times in the cycle. The
prior study from our group based on prospectively filled
diaries from the general population [11] and one clinic
study suggested that attacks of menstrual and non-
menstrual migraine have similar disability [25]. However,
other studies primarily from specialty clinics, suggest
Table 3 Headache experience and impact by menstrual group: results from the AMPP 2009 survey












(MUM) (N = 691)
Headache-Days in the Past 3 months (MIDAS item)1
0-3 605 35.6% 37 39.8% 271 29.7% 297 43.0%
4-6 371 21.9% 27 29.0% 215 23.6% 129 18.7%
7-10 299 17.6% 12 12.9% 180 19.7% 107 15.5%
11-14 88 5.2% 4 4.3% 57 6.2% 27 3.9%
≥15 306 18.0% 10 10.7% 179 19.6% 117 16.9%
Unknown 28 1.6% 3 3.2% 11 1.2% 14 2.0%
Headache Attack Frequency in the Past Month2
0 – <1 568 33.5% 13 14.0% 279 30.6% 276 39.9%
1 – <2 563 33.2% 44 47.3% 324 35.5% 195 28.2%
2 – <3 214 12.6% 10 10.7% 130 14.2% 74 10.7%
≥3 260 15.3% 10 10.7% 149 16.3% 101 14.6%
Unknown 92 5.4% 16 17.2% 31 3.4% 45 6.5%
MIDAS Grade3
I. Little or no disability 1057 62.3% 54 58.1% 533 58.4% 470 68.0%
II. Mild disability 247 14.6% 16 17.2% 145 15.9% 86 12.5%
III. Moderate disability 184 10.8% 9 9.7% 122 13.4% 53 7.7%
IV. Severe disability 154 9.1% 6 6.4% 95 10.4% 53 7.7%
Unknown 55 3.2% 8 8.6% 18 2.0% 29 4.2%
Lost Productive Time (LPT) (days in past 3 months) (MIDAS item)4
0 760 61.9% 34 49.3% 404 59.9% 322 66.5%
≤1.00 182 14.8% 10 14.5% 99 14.7% 73 15.1%
1.01 – 4.99 167 13.6% 12 17.4% 111 16.5% 44 9.1%
≥5 59 4.8% 5 7.2% 37 5.5% 17 3.5%
Unknown 59 4.8% 8 11.6% 23 3.4% 28 5.8%
Sum Score for 3 HIT-6 Questions5
≤49: little to no impact 263 15.5% 15 16.1% 123 13.5% 125 18.2%
50-55: some impact 378 22.4% 17 18.3% 181 19.9% 180 26.2%
56-69: substantial impact 295 17.5% 9 9.7% 165 18.1% 121 17.6%
≥64: very severe impact 754 44.6% 52 55.9% 441 48.5% 261 38.0%
1- Chi-square tests p < 0.001 for MIDAS headache-days in past 3 months with or without unknown values.
2- Chi-square tests p < 0.001 for HA frequency in past month with or without unknown values.
3- Chi-square p < 0.001 for MIDAS grade with or without unknown values.
4- Chi-square p < 0.001 for MIDAS LPT with or without unknown values; restricted to full time or part time employed group (n = 1,227).
5- Chi-square tests p < 0.001for HIT-6 sum score.
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ling than attacks of nonmenstrual migraine [8-10]. All
these studies focused on comparisons of specific mi-
graine attacks rather than migraine groups.
In this study women with any of the menstrually-related
migraine disorders reported on all of their headaches,
rather than separately reporting on the impact of
menstrually-related and menstrually-unrelated migraine.If menstrually-related migraine attacks are more disabling,
then our data will underestimate impact of these headaches.
The extent to which impact is underestimated will depend
on the ratio of the number of menstrually-related migraine
to the number of migraine occurring at other times in the
cycle. This “dilution” effect is likely to be less significant for
MM cases. The overall self-assessment by MM cases may
largely represent experience with peri-menstrual headaches
Table 4 Adjusted odds ratios (logistic regression) and associated confidence intervals for headache impact measures
comparing the two menstrual migraine groups to the menstrually-unrelated migraine group, adjusting for potential
confounders in two separate models1,2
Outcome Group3 Headache-Days Frequency (per 3 months)
<=6 <=45
MODEL MODEL
I1 II2 I1 II2
Odds Ratio for MIDAS LPT4 (0.5+ Days vs <0.5 Days)5 MM 2.4 (1.1-5.1)7 2.0 (0.9-4.3) 2.1 (1.1-3.8)7 1.9 (1.0-3.5)7
MAM 1.3 (0.9-1.9) 1.2 (0.8-1.9) 1.5 (1.2-2.0)6 1.5 (1.1-1.9)6
Odds Ratio for MIDAS LPT4 (2+ Days vs <2 Days)5 MM 5.4 (1.8-15.7)6 5.1 (1.7-15.3)6 2.6 (1.2-5.5)7 2.7 (1.2-5.7)7
MAM 1.8 (0.9-3.7) 1.6 (0.8-3.4) 1.9 (1.3-2.9)6 1.8 (1.2-2.6)6
Odds ratio for HIT-6 sum score of 56+ vs <568 MM 2.5 (1.3-4.7)7 1.7 (0.9-3.3) 2.0 (1.1-3.3)7 1.9 (1.1-3.3)7
MAM 1.4 (1.1-1.9)6 1.3 (0.9-1.8) 1.5 (1.2-1.9)6 1.4 (1.1-1.8)6
Odds ratio for HIT-6 sum score of 60+ vs <609 MM 4.0 (2.1-7.3)6 2.9 (1.5-5.5)6 3.0 (1.8-4.9)6 2.9 (1.7-5.1)6
MAM 1.4 (1.0-1.9)7 1.4 (0.9-1.9) 1.6 (1.3-2.0)6 1.5 (1.2-2.0)6
1-Includes age, race, education level, household income and age of migraine onset as covariates.
2- Includes the covariates from footnote “1” and headache attack frequency per month.
3- MM= self-reported predominanty menstrual migraine, MAM= self-reported menstrually-associated migraine, MUM= self-reported menstrually- unrelated migraine.
4-Lost Productive Time.
5-Restricted modeling: removed ‘other’ employed and MIDAS LPT models only includes those full time or part time employed.
6- Indicates migraine group significance using Type III test at P-value <0.01.
7-Indicates migraine group significance using Type III test at P-value <0.05.
8 – This cut-score divides individuals with some impact or less from those with substantial impact or more.
9 – This cut-score divides individuals with substantial impact or less from those with very severe impact or more.
In bold, values of statistical significance.
Pavlović et al. The Journal of Headache and Pain  (2015) 16:24 Page 9 of 11in contrast to the MAM and MUM groups who are largely
reporting on non-peri-menstrual headaches. It is of interest
that one third of our MM cases also endorsed that they
have headaches outside of their menstruation (-2 to +3 days
from start on menstruation window), further diluting the
MM subgroup and the likely burden of migraine in those
who have only menstrual migraines. As clinical experience
suggests these are likely women who do not meet ICHD
diagnostic criteria for pure MM, but likely experience the
majority of their attacks during the menstrual window and
only rare attacks at other times. As both clinic and popula-
tion diary studies have been limited to three months, it is
uncertain whether women who fulfill diagnostic criteria for
pure MM in these studies actually occasionally experience
attacks outside of their menstrual window. Clinical experi-
ence suggests so, but further longitudinal studies are
needed to clarify this. Furthermore, if peri-menstrual at-
tacks are truly more severe and burdensome as evidence
suggests, there would be a bias in reporting of these events
compared to non-menstruation related events. As such, the
findings from this study cannot be used to determine
if peri-menstrual headaches among women with MM,
MAM or MUM are more disabling than headaches that
occur at other times in the cycle. However, there is a clear
trend of overall greater burden in the MM group than in
MAM and both have greater burden than the MUM.
This study has several strengths. First, the study popu-
lation was population-based and was not subject to thepotential selection bias that is a concern with clinic-
based samples. That is, our study population was less
likely to be prone to selection bias that can occur if
women are more likely to seek care because they have
migraine headaches associated with menses that are not
responsive to treatment. Second, the study population
(N = 1,697) was large and representative of the demo-
graphics of the U.S. population. Finally, we used well
validated instruments to assign migraine diagnosis and
asses our primary variables of headache-impact and
migraine-related disability.
The primary limitation in this study is that our oper-
ational criteria for assigning women to different subgroups
differed from the ICHD recommended definitions. Diary
data over several months would have been the ideal means
of classifying women. Since these data were not available,
we relied on self-reported, retrospective data. Our data
likely mirror the information that patients will provide to
healthcare professionals in clinical practice unless the pa-
tient or healthcare professional gather three months of
prospective daily diary data. Nonetheless, we assume that
self-identification of menstrual migraine status resulted in
some misclassification and we acknowledge that we are
not approximating the ICHD criteria for menstrual mi-
graine. Rather, this is a descriptive study of women in the
US population describing their perception of the relation-
ship between their migraine attacks and their menstrual
cycle. Notably, almost a third of MM cases reported seven
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likely that a number of these women did not have pure
MM according to ICHD, although it is possible if their
headaches last three days or if they also have non-
migraine headaches. Furthermore, misclassification of
MAM to MM cases is likely to have occurred as outlined
above and this would diminish the strength of observed
associations (i.e. biased the odds ratio toward the null) be-
cause data from MAM would have been falsely mixed in
with the MM data. In contrast, misclassification of MM
cases as MAM or MUM is likely to have had a negligible
effect on assessing differences in disability due to the small
size of the group in comparison to other groups.
Furthermore, our definition for MAM (“I am more likely
to get headaches with my period but they also occur at
other times of the month”) was broad and did not require
that migraine occur only two days prior or three days after
the start of menstruation as is required by ICHD criteria.
Individuals could have responded yes to having a “men-
strually-associated migraine” even if their migraine oc-
curred on the final three days of their period, which does
not match menstrual migraine criteria. It will be useful in
the future to determine if peri-menstrual headaches in the
MAM group are more disabling than headaches that
occur at other times in the cycle. We also did not limit
our EM group to those without aura, as is listed in ICHD
criteria. Finally, menstrually related migraine has the
benefit of being relatively predictable which allows for the
preemptive use of therapy or short-term prophylaxis for
migraine prevention. While short-term prophylaxis or
preemptive use of triptans is not FDA approved, it is a
strategy that is used in clinical practice for patients with
menstrual related migraine [8,26,27]. In the current study
we did not report or control for short-term prophylaxis;
therefore it is possible that some percentage of the MM
group may be well controlled on this therapeutic strategy.
Therefore, the disability seen among that group may be
reduced due, in some part, to short-term prophylaxis.
Conclusion
In this large population study representative of the US
population, we have shown that most women self-report
migraine attacks associated with menstruation and those
attacks are associated with impairment including impact
on occupational, academic and household responsibil-
ities. When these women are divided into subgroups,
those with predominantly peri-menstrual migraines ex-
perience the greatest burden. While suggestions for treat-
ment strategies may help, more research will be required
to better understand these subgroups given that they ac-
count for a significant majority of women with migraine
and to determine the best course of treatment for MM
and MAM cases and as a result, reduce the burden of
migraine associated with menstruation.Abbreviations
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